Misplaced Pages

Atazanavir/cobicistat

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Combination drug for HIV Pharmaceutical compound
Atazanavir/cobicistat
Combination of
AtazanavirHIV protease inhibitor
CobicistatCytochrome P450 (CYP3A) inhibitor
Clinical data
Trade namesEvotaz
AHFS/Drugs.comProfessional Drug Facts
License data
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Atazanavir/cobicistat, sold under the brand name Evotaz, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS. It contains atazanavir and cobicistat. Atazanavir is an HIV protease inhibitor and cobicistat is an inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A family.

Atazanavir/cobicistat was approved by the Food and Drug Administration (FDA) for medical use in United States in January 2015. It was approved for medical use in the European Union in July 2015.

Medical uses

Atazanavir/cobicistat is indicated for use in combination with other antiretroviral agents for the treatment of HIV‑1 infection in people weighing at least 35 kilograms (77 lb).

References

  1. "Evotaz 300 mg/150 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 9 July 2021.
  2. ^ "Evotaz- atazanavir and cobicistat tablet". DailyMed. Retrieved 25 May 2021.
  3. ^ "Evotaz EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 25 May 2021.
  4. Crutchley RD, Guduru RC, Cheng AM (2016). "Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection". HIV/AIDS: Research and Palliative Care. 8: 47–65. doi:10.2147/HIV.S99063. PMC 4790521. PMID 27022304.
  5. "U.S. Food and Drug Administration Approves Bristol-Myers Squibb's Evotaz (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults" (Press release). Bristol-Myers Squibb. Archived from the original on 2020-08-08. Retrieved 2018-06-28.
  6. "Evotaz (atazanavir and cobicistat) Tablet". U.S. Food and Drug Administration (FDA). 15 April 2016. Retrieved 25 May 2021. "Summary Report" (PDF).

External links

Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)
Capsid inhibitors
Entry/fusion inhibitors
(Discovery and development)
Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))
Maturation inhibitors
Protease Inhibitors (PI)
(Discovery and development)
1 generation
2 generation
Reverse-transcriptase
inhibitors (RTIs)
Nucleoside and
nucleotide (NRTI)
Non-nucleoside (NNRTI)
(Discovery and development)
1 generation
2 generation
Combined formulations
Pharmacokinetic boosters
Experimental agents
Uncoating inhibitors
Transcription inhibitors
Translation inhibitors
BNAbs
Other
Failed agents
°DHHS recommended initial regimen options. Formerly or rarely used agent.
Portals:


Stub icon

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: